"Type 1 diabetes is particularly tragic because it usually starts in childhood and its effects worsen with time. It can lead to organ damage, blindness and other terrible side effects. That's why I focus so heavily on this disease. I'm trained as a physician and I saw what it can do." - Matthias von Herrath, M.D.
Dr. von Herrath serves as Director of the Center for Type 1 Diabetes Research in addition to being a full Professor in the Division of Developmental Immunology.
Dr. von Herrath's research focuses on strategies to prevent
type 1 diabetes through the induction of regulatory T cells.
Dr. von Herrath wrote his thesis in the field of Biochemistry and then
received his M.D. in Medicine from the Freiburg Medical School in
Freiburg, Germany in 1988. He did his residency work at the Freiburg
Medical Center in the Internal Medicine/Immunology department and at
the Diakonic Hospital's Intensive Care Unit in Freiburg. For his
postdoctoral work, Dr. von Herrath went to The Scripps Research
Institute and worked in its Neuropharmacology and Immunology
Dr. von Herrath is an editor and reviewer for numerous
publications as well as being a member of the American Society of Clinical
Investigator and a Council Member for the International Diabetes Society. In
addition, he is an Adjunct Professor of Medicine at the University of
California, San Diego. He is the recipient of the 2008 American Diabetes
Association-Lilly Outstanding Scientist Achievements Award, the 2006 Grotzky
Award from the Juvenile Diabetes Foundation International, the 2007-2012 Scholar
Award from the Juvenile Diabetes Foundation, awarded the 2014 Langerhans-Preis
– German Diabetes Foundation, and was ranked in 2014 as the #1 Juvenile
Diabetes Expert by “Expertscape.”
Matthias von Herrath, M.D., and his team study why the immune system
sometimes attacks the body's own cells. They focus on type 1 diabetes,
a disease caused by the immune system attacking the insulin-producing
beta cells in the pancreas, and on diseases caused by viral infections.
Their goal is to develop and evaluate new treatments and therapies for
these conditions, in particular immune-based interventions.
The laboratory has found that stimulating the immune system with beta
cell proteins via DNA vaccines results in a beneficial, or regulatory,
immune response that can prevent type 1 diabetes. The DNA vaccines are
currently being developed for the clinic in collaboration with BayHill
In addition, Dr. von Herrath's team is studying how introducing immune
response modifiers, such as small molecules named "cytokines" or
certain antibodies, get the immune system back on track, stopping it
from attacking the body's own cells. His laboratory is collaborating
with a major diabetes consortium in the United States and Australia,
supported in part by the Juvenile Diabetes Foundation and the Medical
Research Council in Australia, on developing this strategy. This
approach has proved effective in animals in an advanced stage of type 1
diabetes, and the hope is that this will translate to human patients.
Viral infections and the diseases they cause can be modulated through
similar pathways. In parallel to the approach followed by the
laboratory for type 1 diabetes, the focus is on developing treatments
that will be effective after the infection has occurred.
To read more about Dr. von Herrath's work visit the Type 1 Diabetes Center.
Higher proinflammatory cytokine production and spontanous activation in some type 1 and type 2 diabetic subjects. Clin Immunol. 2014
Potential viral pathogenic mechanism in human type 1 diabetes. Diabetologia. 2014
Increased immune cell infiltration of the exocrine pancrease: A possible contribution to the pathogenesis of type 1 diabetes. Diabetes. 2014.
Regulatory T cells control diabetes without compromising acute anti-viral defense. Clin Immunol. 2014
Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies. Mol Metab. 2014
Direct infection of dendritic cells during chronic viral infection suppresses antiviral T cell proliferation and induces IL-10 expression in CD4 T cells. PLoS One. 2014
Beta-cell specific production of IL6 in conjunction with a mainly intracellular but not mainly surface viral protein causes diabetes. J Autoimmun. 2014
Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes. 2014
CD8 T-cell reactivity to islet antigens is unique to type 1 while CD-4 T-cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun. 2014
Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother. 2014
Exogenous OX40 stimulation during lymphocytic choriomeningitis virus infection impairs follicular Th cell differentiation and diverts DC4 T cells into the effector lineage by upregulating blimp-1. J Immunol. 2013
The clinical and immunological signficiance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. J. Autoimmun. 2013.
Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model. Diabetes. 2013
Trials in type 1 diabetes: antigen-specific therapies. Clin Immunol. 2013
Antibody cross-reactivity and the viral aetiology of type 1 diabetes. J Pathol. 2013
Keeping the patient perspective: where are we in the world of type 1 diabetes. Clin Immunol. 2013
Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment. PLoS One. 2013
Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS One. 2013
Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation. Diabetes Obes Metab. 2013
NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes. J Autoimmun. 2013
Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol. 2013
Combination therapy with anti-CD6 and oral insulin immunisation reverses recent onset diabetes in non obese diabetic mice but fails to induce lasting tolerance. Clin Immunol. 2013
Immunology in the clinic review series: focus on type 1 diabetes and viruses: the role of viruses in type 1 diabetes: a difficult dilemma. Clin Exp Immunol. 2012
Can an immune-regulatory vaccine prevent HIV infection? Expert Rev Anti Infect Ther. 2012
Following the Fate of One Insulin-Reactive CD4 T cell Conversion Into Teffs and Tregs in the Periphery Controls Diabetes in NOD Mice. Diabetes. 2012
Combination therapy with InsB9-23 peptide immunization and CTLA4-IgG does not reverse diabetes in NOD mice. Clin Immunol. 2012
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012
Intravital imaging of CTLs killing islet cells in diabetic mice. J Clin Invest. 2012
Virus Infections in type 1 diabetes. Cold Spring Harb Perspect Med. 2012
Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J Autoimmun. 2011
Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individuals. Diabetes Metab Res Rev. 2011
How viral infections enhance or prevent type 1 diabetes-from mouse to man. J Med Virol. 2011
Development of Autoimmune Diabetes in the Absence of Detectable IL-17A in a CD8-Driven Virally Induced Model. J Immunol. 2011
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited.
Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun. 2011
TLR2 signaling improves immunoregulation to prevent type 1 diabetes. Eur J Immunol. 2011
Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med. 2011
Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011
Increased memory conversion of naïve CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure. PLoS One. 2011
Humanizing animal models: a key to autoimmune diabetes treatment.
Sci Transl Med. 2011
Pathology and pathogenesis of virus infections. The Immune Response to Infection. 2011
A novel technique for the in vivo imaging of autoimmune diabetes development in the pancreas by two-photon microscopy. PLoS One. 2010
Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes. 2010
View all publications
The link above may include papers by scientists with the same or similar name.